 NEW YORK and SAN DIEGO, Sept. 01, 2021 GLOBE NEWSWIRE -- Zentalis Pharmaceuticals, Inc. Nasdaq: ZNTL, a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers, today announced the publication of the discovery of ZN-c3, the Companys highly potent and selective WEE1 inhibitor candidate, in the Journal of Medicinal Chemistry. 